来凯医药科技（上海）有限公司 Mediaroom

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2...

2024-11-20 22:00 1375

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, c...

2024-05-23 20:42 1825

Laekna Releases 2023 ESG Report

SHANGHAI and WARREN, N.J., April 29, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven,...

2024-04-29 20:30 1278

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the compan...

2024-04-08 08:30 1245

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic ...

2024-01-04 12:40 1611

2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results

- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, M...

2023-12-11 18:55 1375

Laekna, Inc. (2105.HK) Announces Interim Results 2023

* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recu...

2023-08-25 08:00 3484

Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102

SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...

2023-05-21 22:23 2266

Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study

SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology com...

2022-09-06 17:02 1899

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer

SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biote...

2022-05-26 20:27 1655

Laekna Therapeutics Raises $61 Million in Series D financing

SHANGHAI and WARREN, N.J., May 18, 2022 /PRNewswire/ -- Laekna Therapeutics (" Laekna"), a clinical-...

2022-05-18 20:00 1975

Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board

SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage glo...

2022-03-29 20:00 1447

Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board

Laekna Launched the new domain name www.laekna.com

SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct...

2022-02-07 12:47 1514

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase

SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the N...

2021-12-24 16:30 3696

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging in...

2021-09-16 17:06 1419

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer

SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today t...

2021-08-27 11:20 1560

Laekna Therapeutics will present two clinical study results in ESMO 2021

SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovativ...

2021-07-26 13:26 2249

Latest News